178 related articles for article (PubMed ID: 32862405)
1. PNPLA3 I148M is involved in the variability in anti-NAFLD response to exenatide.
Chen Y; Yan X; Xu X; Yuan S; Xu F; Liang H
Endocrine; 2020 Dec; 70(3):517-525. PubMed ID: 32862405
[TBL] [Abstract][Full Text] [Related]
2. PNPLA3 148M/M Is More Susceptible to Palmitic Acid-Induced Endoplasmic Reticulum Stress-Associated Apoptosis in HepG2 Cells.
Chen Y; Yan X; Wang T; Deng H; Deng X; Xu F; Liang H
Int J Endocrinol; 2023; 2023():2872408. PubMed ID: 36825197
[TBL] [Abstract][Full Text] [Related]
3. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro.
Pirazzi C; Adiels M; Burza MA; Mancina RM; Levin M; Ståhlman M; Taskinen MR; Orho-Melander M; Perman J; Pujia A; Andersson L; Maglio C; Montalcini T; Wiklund O; Borén J; Romeo S
J Hepatol; 2012 Dec; 57(6):1276-82. PubMed ID: 22878467
[TBL] [Abstract][Full Text] [Related]
4. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.
Scorletti E; West AL; Bhatia L; Hoile SP; McCormick KG; Burdge GC; Lillycrop KA; Clough GF; Calder PC; Byrne CD
J Hepatol; 2015 Dec; 63(6):1476-83. PubMed ID: 26272871
[TBL] [Abstract][Full Text] [Related]
5. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.
Donati B; Motta BM; Pingitore P; Meroni M; Pietrelli A; Alisi A; Petta S; Xing C; Dongiovanni P; del Menico B; Rametta R; Mancina RM; Badiali S; Fracanzani AL; Craxì A; Fargion S; Nobili V; Romeo S; Valenti L
Hepatology; 2016 Mar; 63(3):787-98. PubMed ID: 26605757
[TBL] [Abstract][Full Text] [Related]
6. Long-term hypercaloric diet exacerbates metabolic liver disease in PNPLA3 I148M animals.
Su H; Haque M; Becker S; Edlund K; Duda J; Wang Q; Reißing J; Marschall HU; Candels LS; Mohamed M; Sjöland W; Liao L; Drexler SA; Strowig T; Rahnenführer J; Hengstler JG; Hatting M; Trautwein C
Liver Int; 2023 Aug; 43(8):1699-1713. PubMed ID: 37073116
[TBL] [Abstract][Full Text] [Related]
7. PNPLA3 I148M Variant Influences Circulating Retinol in Adults with Nonalcoholic Fatty Liver Disease or Obesity.
Mondul A; Mancina RM; Merlo A; Dongiovanni P; Rametta R; Montalcini T; Valenti L; Albanes D; Romeo S
J Nutr; 2015 Aug; 145(8):1687-91. PubMed ID: 26136587
[TBL] [Abstract][Full Text] [Related]
8. Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease.
Wu JT; Liu SS; Xie XJ; Liu Q; Xin YN; Xuan SY
Lipids Health Dis; 2020 Feb; 19(1):29. PubMed ID: 32093693
[TBL] [Abstract][Full Text] [Related]
9. [Effect of different genotypes of PNPLA3 I148M on hepatocyte proliferation].
Yan XM; Yuan SH; Xu X; Ai HY; Liang H
Zhonghua Yi Xue Za Zhi; 2018 Sep; 98(34):2754-2759. PubMed ID: 30220174
[No Abstract] [Full Text] [Related]
10. Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans.
Ericson E; Bergenholm L; Andréasson AC; Dix CI; Knöchel J; Hansson SF; Lee R; Schumi J; Antonsson M; Fjellström O; Nasr P; Liljeblad M; Carlsson B; Kechagias S; Lindén D; Ekstedt M
Hepatol Commun; 2022 Oct; 6(10):2689-2701. PubMed ID: 35833455
[TBL] [Abstract][Full Text] [Related]
11. PNPLA3 I148M Polymorphism in Patients with Nonalcoholic Fatty Liver Disease, Obesity and Prediabetes.
Karamfilova V; Gateva A; Assyov Y; Alexiev A; Savov A; Yaneva N; Ivanova I; Ivanova-Boyanova R; Ivanova R; Vlahova Z; Mateva L; Kamenov Z
J Gastrointestin Liver Dis; 2019 Dec; 28(4):433-438. PubMed ID: 31826069
[TBL] [Abstract][Full Text] [Related]
12. PNPLA3 I148M and response to treatment for hepatic steatosis: A systematic review.
Boeckmans J; Gatzios A; Schattenberg JM; Koek GH; Rodrigues RM; Vanhaecke T
Liver Int; 2023 May; 43(5):975-988. PubMed ID: 36719059
[TBL] [Abstract][Full Text] [Related]
13. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population.
Wang CW; Lin HY; Shin SJ; Yu ML; Lin ZY; Dai CY; Huang JF; Chen SC; Li SS; Chuang WL
Liver Int; 2011 Oct; 31(9):1326-31. PubMed ID: 21745282
[TBL] [Abstract][Full Text] [Related]
14. Four-Week Omega-3 Supplementation in Carriers of the Prosteatotic PNPLA3 p.I148M Genetic Variant: An Open-Label Study.
Kuttner CS; Mancina R; Wagenpfeil G; Lammert F; Stokes CS
Lifestyle Genom; 2019; 12(1-6):10-17. PubMed ID: 31454802
[TBL] [Abstract][Full Text] [Related]
15. Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C.
Zampino R; Coppola N; Cirillo G; Boemio A; Pisaturo M; Marrone A; Macera M; Sagnelli E; Perrone L; Adinolfi LE; Miraglia del Giudice E
J Viral Hepat; 2013 Aug; 20(8):517-23. PubMed ID: 23808989
[TBL] [Abstract][Full Text] [Related]
16. The I148M
Paolini E; Longo M; Meroni M; Tria G; Cespiati A; Lombardi R; Badiali S; Maggioni M; Fracanzani AL; Dongiovanni P
Front Nutr; 2023; 10():1101341. PubMed ID: 36937355
[TBL] [Abstract][Full Text] [Related]
17. PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.
Chen LZ; Xin YN; Geng N; Jiang M; Zhang DD; Xuan SY
World J Gastroenterol; 2015 Jan; 21(3):794-802. PubMed ID: 25624712
[TBL] [Abstract][Full Text] [Related]
18. Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population.
Unalp-Arida A; Ruhl CE
Hepatology; 2020 Mar; 71(3):820-834. PubMed ID: 31705824
[TBL] [Abstract][Full Text] [Related]
19. The Role of
Liu M; Park S
Nutrients; 2024 Apr; 16(8):. PubMed ID: 38674929
[TBL] [Abstract][Full Text] [Related]
20. PNPLA3 I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: Clinical and experimental findings.
Mantovani A; Taliento A; Zusi C; Baselli G; Prati D; Granata S; Zaza G; Colecchia A; Maffeis C; Byrne CD; Valenti L; Targher G
Liver Int; 2020 May; 40(5):1130-1141. PubMed ID: 32125756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
